Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

NCT03587272 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Alemtuzumab, low dose total body irradiation, Sirolimus

Sponsor

Robert Nickel

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]